A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Next Previous
Trial Profile

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Liraglutide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms DUAL I China
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 10 Jan 2018 Planned End Date changed from 14 Jan 2019 to 29 Jul 2019.
    • 09 Nov 2017 Planned End Date changed from 30 Dec 2018 to 14 Jan 2019.
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top